A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

计划入组 7 人 · 首次发布于 2014 年 12 月 9 日

Tissue Plasminogen Activator & Plasminogen Activator Inhibitor Type-1 In Gingival Tissues Of Chronic Periodontitis

计划入组 30 人 · 首次发布于 2019 年 1 月 14 日

Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency

计划入组 1 人 · 首次发布于 2022 年 6 月 3 日

Human tissue urokinase type plasminogen activator

Plasmin(Ryplazim)

Rx

urokinase-type plasminogen activator inhibitors (Curacyte)

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

FDA Approves Kedrion's Facility for RYPLAZIM Production, Expanding Access for PLGD-1 Patients

FDA Approves Kedrion's Facility for RYPLAZIM® Production, Expanding Access to PLGD-1 Treatment

FDA Approves Kedrion's Facility for RYPLAZIM Production, Expanding Access to PLGD-1 Treatment